Home News Bharat Biotech Complete Enrollment of 25,800 Volunteers for Covaxin Phase-3 Trials

Bharat Biotech Complete Enrollment of 25,800 Volunteers for Covaxin Phase-3 Trials

News18 Logo

Covaxin has been developed by Hyderabad-based Bharat Biotech. (File photo)

Covaxin has been developed by Hyderabad-based Bharat Biotech. (File photo)

In a message posted on the company’s Twitter account, she thanked clinical trial sites, principal investigators and health workers for their support and trust in the “public- private partnership” vaccine discovery.

  • PTI Hyderabad
  • Last Updated: January 07, 2021, 20:36 IST
  • FOLLOW US ON:

Bharat Biotech has completed enrollment of 25,800 volunteers for the Phase-3 trials of its vaccine Covaxin, Suchitra Ella, joint managing director, Bharat Biotech International Ltd said on Thursday. In a message posted on the company’s Twitter account, she thanked clinical trial sites, principal investigators and health workers for their support and trust in the “public- private partnership” vaccine discovery.

“My deep appreciation to all the volunteers for reposing and expressing Pro Vaccine Public Health Voluntarism in the phase-3 clinical trials of India’s 1st fully indigenous vaccine,” she said referring to Covaxin. The Drug Controller General of India (DCGI) has recently given Emergency Use Authorisation for Covaxin.

The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteersacross India. The company had said it is the only Phase-3 efficacy study for a vaccine, and the largest efficacy trial (Phase-3) ever conducted for any vaccine in India..

.

This article is auto-generated by Algorithm Source: www.news18.com

Related Posts

0

Ad Blocker Detected!

Refresh